在重症监护中的循环利尿剂的临床药理学
Fiorenza Ferrari1,2, Christian Zanza3, Manfredi Tesauro4,5
1International Renal Research Institute of Vicenza (IRRIV), Department of Nephrology, Dialysis and Transplantation, San Bortolo Hospital, Azienda ULSS 8 Berica, Vicenza, Italy.
Clinical pharmacokinetics
|May 30, 2025
概括
循环利尿剂对于重症监护中的液体过载至关重要,但面临着诸如可变的药理动力学和耐药性等挑战. 本综述探讨了优化循环利尿剂使用的策略,并改善了重症患者的患者结果.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临界护理医学 临界护理医学
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 循环利尿剂对于在重症患者中管理液体过载至关重要.
- 它们的有效性通常受到可变的药理动力学和利尿剂耐药性所限制.
- 了解这些挑战对于有效的患者管理至关重要.
研究的目的:
- 在重症患者中全面审查循环利尿剂的药理学.
- 探索尿素耐药性的原因和影响.
- 提出克服耐药性和优化循环利尿疗法的策略.
主要方法:
- 关于循环利尿剂在重症监护中的现有文献的叙事综述.
- 对药物动力学特性和影响它们的因素的分析.
- 检查利尿剂耐药性的不良事件和机制.
主要成果:
- 由于器官功能障碍,流体转移和药物改变的药理动力学使治疗复杂化.
- 利尿剂耐药性源于多因素原因,包括改变的药理动力学.
- 副作用包括电解质失衡和耳毒性.
结论:
- 量身定制的方法对于优化临重病患者循环利尿剂治疗至关重要.
- 克服利尿剂耐药性的策略包括组合疗法和优化剂量.
- 本综述为临床医生提供了洞察力,通过知情循环利尿剂的使用来提高患者的治疗结果.
相关概念视频
Heart Failure Drugs: Diuretics
505
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
505
Antihypertensive Drugs: Potassium-Sparing Diuretics
796
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
796
Acute Kidney Injury V: Interprofessional Care
52
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
52
Acute Kidney Injury VI: Nursing Management
69
Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...
69
Acute Kidney Injury IV: Diagnostic Studies and Prevention
64
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
64
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
526
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
526


